Ondansetron Injection, USP is a selective 5-HT₃ receptor antagonist designed for intravenous (IV) or intramuscular (IM) use. It is indicated for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative recovery.
Key Benefits:
- Chemotherapy-Induced Nausea and Vomiting (CINV): Prevents nausea and vomiting in patients undergoing initial and repeat courses of emetogenic cancer chemotherapy.
- Postoperative Nausea and Vomiting (PONV): Provides effective relief from postoperative nausea and vomiting for patients at risk.
- Multiple Administration Routes: Available for both IV and IM use, providing flexibility based on patient needs and procedural requirements.
Dosage and Administration:
For Intravenous or Intramuscular Use:
- Chemotherapy-Induced Nausea and Vomiting: 0.15 mg/kg per dose for adults and pediatric patients (6 months and older), administered as three doses over 15 minutes. Start 30 minutes before chemotherapy, then repeat doses 4 and 8 hours after the first dose.
- Postoperative Nausea and Vomiting: A single dose of 4 mg IV or IM for adults and children over 1 month of age, given either before anesthesia or postoperatively as needed. Adjustments are recommended for patients with hepatic impairment, with a maximum daily dose of 8 mg.
Why Choose Ondansetron Injection?
- Clinically Proven for Nausea Control: Widely trusted in oncology and surgical settings due to its effective antiemetic action.
- Rapid Onset: Quick-acting relief for nausea and vomiting, beneficial in high-stakes clinical environments.
- Available in Multi-Dose Vials: Offered in multi-dose (20 mL) vials with 2 mg/mL concentration for flexible dosing.
Warnings:
- QT Prolongation: May prolong the QT interval in a dose-dependent manner; caution in patients with existing cardiac risks.
- Risk of Serotonin Syndrome: Especially with concurrent use of other serotonergic agents; monitor for symptoms such as agitation, hallucinations, and autonomic instability.
- Hypersensitivity Reactions: May cause anaphylaxis in patients with known sensitivity to other 5-HT₃ receptor antagonists.
Disclaimer:
This product description was generated by AI and is intended for informational purposes only. Please consult the latest package insert.
